Shedding Light on Photobiomodulation in Neuropsychiatric Disorders

Over the last decade, there has been an increasingly positive shift in how transcranial photobiomodulation (tPBM) is viewed by mainstream medical science.

If you’d like an in-depth overview of the potential applications of transcranial brain photobiomodulation in the field of psychiatry, this presentation by Dr. Corinne Fischer is for you:

Dr. Fischer is a professor of Psychiatry at the University of Toronto and Director of Geriatric Psychiatry at St. Michael’s Hospital.

She touches on a few different topics, including Vielight technology:

• A conceptual overview of photobiomodulation in comparison to other neuromodulatory therapies.
• An overview of the basic science, anecdotal and clinical trial evidence for photobiomodulation in Alzheimer’s disease.
• An overview of potential applicability to other neuropsychiatric disorders.

Dr. Fischer is also the chief Principal Investigator for Vielight’s pivotal clinical trial for Alzheimer’s disease (228 participants): https://clinicaltrials.gov/ct2/show/NCT03484143

Vielight is proud to be a part of this change, contributing to faster advancement and, ultimately, acceptance of tPBM as a viable and effective non-invasive brain stimulation modality for numerous applications.